LEO Pharma Presents New 12-Month Real-World Data for Tralokinumab at AAD 2026

Tralokinumab treatment demonstrated improvements in atopic dermatitis severity and quality of life across diverse patient populations.

Mar. 31, 2026 at 3:22am

Got story updates? Submit your updates here. ›

LEO Pharma announced the presentation of new post-hoc analyses of 12-month real-world data from the TRACE study of tralokinumab, at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The data showed that the majority of atopic dermatitis (AD) patients with hand and/or foot involvement experienced clearance over 12 months of treatment with tralokinumab, and that treatment also reduced AD severity and provided improved quality of life among patients with skin of color.

Why it matters

These real-world results build on data from the tralokinumab clinical trial program and help address evidence gaps in specific patient populations and high burden areas, like the hands and feet, that are often underrepresented in clinical studies.

The details

In a post-hoc analysis of the TRACE patients with hand and/or foot involvement, the proportion of patients reporting any involvement decreased markedly from baseline to Month 3 and Month 12. Improvements were also seen in disease severity, patient reported outcomes, and quality of life. In a separate analysis among patients with skin of color, 80.4% achieved at least one clinically meaningful disease control endpoint at 12 months, and improvements in quality of life were observed.

  • The TRACE study enrolled patients between November 2021 and July 2023.
  • The 12-month data was presented at the 2026 American Academy of Dermatology Annual Meeting, held from March 27-31, 2026 in Denver, Colorado.

The players

LEO Pharma

A global leader in medical dermatology that is committed to moving the science forward on the understanding of atopic dermatitis and how tralokinumab works in difficult to treat populations.

April Armstrong, MD, MPH

Professor and Chief of Dermatology at UCLA, and primary author of the study.

Shannon Schneider

Vice President of North America Medical Affairs for LEO Pharma.

ADBRY® (tralokinumab-ldrm)

A high-affinity fully human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine, which plays a role in the immune and inflammatory processes underlying atopic dermatitis signs and symptoms.

TRACE

A prospective, non-interventional, international, single-cohort study of adult patients with AD who were prescribed tralokinumab.

Got photos? Submit your photos here. ›

What they’re saying

“LEO Pharma is committed to moving the science forward on our understanding of the pathogenesis of atopic dermatitis and how tralokinumab works in difficult to treat populations. These 12-month real-world results build on data from the tralokinumab clinical trial program and help address evidence gaps in specific patient populations and high burden areas, like the hands and feet.”

— Shannon Schneider, Vice President of North America Medical Affairs for LEO Pharma

“Atopic dermatitis affects people with all skin tones and frequently impacts high-burden areas such as the hands and feet. These results reinforce clinical experience, demonstrating that tralokinumab helps deliver meaningful benefits across diverse patient groups and challenging areas of the body.”

— April Armstrong, MD, MPH, Professor and Chief of Dermatology, UCLA

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

These real-world findings on tralokinumab's effectiveness in treating atopic dermatitis, including in hard-to-treat areas and diverse patient populations, provide important insights that can help guide clinical practice and improve outcomes for individuals living with this chronic, inflammatory skin condition.